The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis
- 1 February 2012
- journal article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 66 (2), e67-e76
- https://doi.org/10.1016/j.jaad.2010.10.020
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitisRheumatology, 2010
- Impact of Psoriasis on Patientsʼ Work and ProductivityAmerican Journal of Clinical Dermatology, 2009
- Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trialBritish Journal of Dermatology, 2009
- The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004Journal of the American Academy of Dermatology, 2008
- Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's diseaseClinical Therapeutics, 2008
- Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisBritish Journal of Dermatology, 2007
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2007
- Impact of adalimumab treatment on patient‐reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasisJournal of Dermatological Treatment, 2007
- A Review of Self-Report Instruments Measuring Health-Related Work ProductivityPharmacoEconomics, 2004
- The Validity and Reproducibility of a Work Productivity and Activity Impairment InstrumentPharmacoEconomics, 1993